|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.90 USD | +6.33% |
|
-.--% | +6.33% |
| 04-22 | Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 04-05 | Boiron SA announces Annual dividend, payable on June 05, 2026 | CI |
| Market Cap | 486M 563M 448M 419M 786M 53.5B 798M 5.29B 2.06B 26.04B 2.11B 2.07B 90.17B | P/E Ratio 2024 |
41x | P/E Ratio 2025 | 16.1x |
|---|---|---|---|---|---|
| Enterprise Value | 438M 507M 404M 378M 708M 48.23B 719M 4.77B 1.86B 23.48B 1.9B 1.86B 81.29B | EV / Sales 2024 |
0.85x | EV / Sales 2025 | 0.95x |
| Free-Float |
19.96% | Yield 2024 |
4.48% | Yield 2025 | 4.46% |
| 1 day | +6.33% | ||
| 1 month | +6.33% | ||
| 3 months | +6.33% | ||
| 6 months | +6.33% | ||
| Current year | +6.33% |
| 1 month | 31.9 | 31.9 | |
| Current year | 31.9 | 31.9 | |
| 1 year | 24 | 32.28 | |
| 3 years | 24 | 53.5 | |
| 5 years | 24 | 53.5 | |
| 10 years | 24 | 99.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Houdayer
CEO | Chief Executive Officer | 56 | 2024-12-31 |
Frédéric Riou
CTO | Chief Tech/Sci/R&D Officer | - | - |
Isabelle Chanel
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Thierry Boiron
CHM | Chairman | 65 | 2011-06-30 |
| Director/Board Member | 54 | 2010-03-09 | |
| Director/Board Member | 51 | 2013-05-22 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +6.33% | -.--% | - | - | 563M | ||
| +0.10% | +3.67% | -10.44% | -4.62% | 13.34B | ||
| +2.67% | -0.32% | -32.02% | -55.44% | 5.06B | ||
| +0.90% | +1.77% | -6.31% | +4.08% | 4.79B | ||
| +3.15% | +2.01% | +8.20% | -40.81% | 3.88B | ||
| +2.11% | -2.30% | +13.25% | -18.51% | 3.86B | ||
| +2.81% | -3.14% | -1.45% | -6.39% | 3.69B | ||
| +1.48% | +1.55% | -10.11% | -1.44% | 3.18B | ||
| +5.11% | +1.13% | -8.04% | -26.93% | 2.37B | ||
| +0.87% | -4.27% | -11.89% | +29.70% | 1.73B | ||
| Average | +2.55% | +1.23% | -6.53% | -13.37% | 4.66B | |
| Weighted average by Cap. | +1.69% | +1.67% | -7.77% | -14.14% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 488M 565M 449M 421M 788M 53.66B 800M 5.31B 2.07B 26.12B 2.12B 2.07B 90.43B | 501M 580M 462M 432M 810M 55.15B 823M 5.45B 2.13B 26.84B 2.18B 2.13B 92.94B |
| Net income | 11.34M 13.12M 10.45M 9.78M 18.32M 1.25B 18.61M 123M 48.09M 607M 49.26M 48.21M 2.1B | 32.64M 37.79M 30.08M 28.16M 52.77M 3.59B 53.58M 355M 138M 1.75B 142M 139M 6.05B |
| Net Debt | -49.74M -57.59M -45.83M -42.9M -80.4M -5.47B -81.65M -541M -211M -2.66B -216M -212M -9.22B | -47.86M -55.41M -44.1M -41.28M -77.36M -5.27B -78.56M -521M -203M -2.56B -208M -204M -8.88B |
Employees
2,499
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BOI Stock
- BOIR.F Stock
Select your edition
All financial news and data tailored to specific country editions
















